ATE295374T1 - Hu-b1.219, ein neuartiger hämatopoietinrezeptor - Google Patents

Hu-b1.219, ein neuartiger hämatopoietinrezeptor

Info

Publication number
ATE295374T1
ATE295374T1 AT95931007T AT95931007T ATE295374T1 AT E295374 T1 ATE295374 T1 AT E295374T1 AT 95931007 T AT95931007 T AT 95931007T AT 95931007 T AT95931007 T AT 95931007T AT E295374 T1 ATE295374 T1 AT E295374T1
Authority
AT
Austria
Prior art keywords
hematopoietin receptor
relates
expression
novel
ligands
Prior art date
Application number
AT95931007T
Other languages
English (en)
Inventor
Ralph H Snodgrass
Joseph Cioffi
Thomas J Zupancic
Alan W Shafer
Original Assignee
Indevus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/355,888 external-priority patent/US5763211A/en
Application filed by Indevus Pharmaceuticals Inc filed Critical Indevus Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE295374T1 publication Critical patent/ATE295374T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
AT95931007T 1994-09-14 1995-08-30 Hu-b1.219, ein neuartiger hämatopoietinrezeptor ATE295374T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/306,231 US5643748A (en) 1994-09-14 1994-09-14 HU-B1.219, a novel human hematopoietin receptor
US08/355,888 US5763211A (en) 1994-09-14 1994-12-14 Isolated nucleic acid encoding Hu-B1.219, a novel human hematopoietin
PCT/US1995/010965 WO1996008510A1 (en) 1994-09-14 1995-08-30 Hu-B1.219, A NOVEL HUMAN HEMATOPOIETIN RECEPTOR

Publications (1)

Publication Number Publication Date
ATE295374T1 true ATE295374T1 (de) 2005-05-15

Family

ID=23184398

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95931007T ATE295374T1 (de) 1994-09-14 1995-08-30 Hu-b1.219, ein neuartiger hämatopoietinrezeptor

Country Status (11)

Country Link
US (4) US5643748A (de)
EP (1) EP0730606B1 (de)
JP (2) JP3479892B2 (de)
AT (1) ATE295374T1 (de)
AU (1) AU689948B2 (de)
CA (1) CA2176463C (de)
DE (1) DE69534196T2 (de)
DK (1) DK0730606T3 (de)
ES (1) ES2242960T3 (de)
PT (1) PT730606E (de)
WO (1) WO1996008510A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) * 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
AUPN564195A0 (en) * 1995-09-26 1995-10-19 Walter And Eliza Hall Institute Of Medical Research, The A novel haemopoietin receptor and genetic sequences encoding same
US6287782B1 (en) 1995-11-27 2001-09-11 Millennium Pharmaceuticals, Inc. Methods of using the Ob receptor to identify therapeutic compounds
US6977240B1 (en) * 1995-11-27 2005-12-20 Millenium Pharmaceuticals, Inc. Methods of using the OB receptor antibodies to treat bodyweight disorders
US6548269B1 (en) * 1995-11-27 2003-04-15 Millennium Pharmaceuticals, Inc. Ob receptor and methods for the diagnosis and treatment of body weight disorders, including obesity and cachexia
US6509189B1 (en) 1995-11-27 2003-01-21 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding the cytoplasmic domain of human Ob receptor
US5972621A (en) * 1995-11-27 1999-10-26 Millennium Pharmaceuticals, Inc. Methods of identifying compounds that modulate body weight using the OB receptor
US6506877B1 (en) * 1995-11-27 2003-01-14 Millennium Pharmaceuticals, Inc. Ob receptor
US6482927B1 (en) 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE69734096T2 (de) * 1996-01-04 2006-06-29 Amgen Inc., Thousand Oaks Rezeptor des ob-proteins und verwandte zusammensetzungen und verfahren
US6541604B1 (en) * 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
AU721129B2 (en) * 1996-01-08 2000-06-22 Genentech Inc. WSX receptor and ligands
US20050019325A1 (en) * 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US7074397B1 (en) * 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US7063958B1 (en) * 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
US7084252B1 (en) 1996-01-16 2006-08-01 The Rockefeller University DB, the receptor for leptin
US7148004B1 (en) 1997-01-16 2006-12-12 The Rockefeller University Oligonucleotides of the OB-R isoforms and methods of diagnosing body weight
AU1833197A (en) * 1996-01-18 1997-08-11 Progenitor, Inc. Detection of a leptin receptor variant and methods for regulating obesity
WO1997027286A1 (en) * 1996-01-23 1997-07-31 Progenitor, Inc. Methods for using the obese gene and its gene product to stimulate hematopoietic development
US7619079B2 (en) * 1996-02-14 2009-11-17 The Rockefeller University Db, the receptor for leptin, nucleic acids encoding the receptor, and uses thereof
US6281346B1 (en) 1996-03-22 2001-08-28 Merck & Co., Inc. Rat ob-receptors and nucleotides encoding them
US6007998A (en) * 1996-04-22 1999-12-28 Merck & Co., Inc. Leptin assay
EP0914611A4 (de) * 1996-04-22 2002-10-16 Merck & Co Inc Transaktivierung von leptin
JP2000512486A (ja) * 1996-05-06 2000-09-26 メルク エンド カンパニー インコーポレーテッド Ｏｂレセプターイソ型及びそれらをコードする核酸
US6258944B1 (en) 1996-05-06 2001-07-10 Merck & Co., Inc. OB receptor isoforms and nucleic acids encoding them
US6001816A (en) * 1996-06-20 1999-12-14 Merck & Co., Inc. Gene therapy for leptin deficiency
US20060205660A1 (en) * 1996-06-20 2006-09-14 Sauvage Frederic D OB protein-immunoglobulin chimeras
US5789198A (en) * 1996-08-01 1998-08-04 Incyte Pharmaceuticals, Inc. Human leptin receptor-related protein
US5874535A (en) * 1996-08-01 1999-02-23 Incyte Pharmaceuticals, Inc. Human leptin receptor gene-related protein
AUPO224696A0 (en) * 1996-09-11 1996-10-03 Amrad Operations Pty. Limited A novel haemopoietin receptor and genetic sequences encoding same
US5976838A (en) * 1996-12-18 1999-11-02 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
PL333187A1 (en) * 1996-11-01 1999-11-22 Smithkline Beecham Plc Method of detecting compounds which modulate the performance of protein of obesity (ob)
US20020081602A1 (en) * 1996-11-01 2002-06-27 Smithkline Beecham P.1.C. Method for the detection of compounds that modulate the effects of the obese (ob) protein
JP2001505437A (ja) 1996-12-02 2001-04-24 メルク エンド カンパニー インコーポレーテッド 突然変異ｏｂ受容体およびそれをコードするヌクレオチド
AU5733898A (en) * 1997-01-16 1998-08-07 Genetics Institute Inc. Member of the hematopoietin receptor superfamily
NZ507293A (en) * 1998-04-10 2003-12-19 Inst Genetics Llc U4, a member of the hematopoietin receptor superfamily
US6770444B2 (en) 1998-07-16 2004-08-03 Synaptic Pharmaceutical Corporation Methods of identifying or screening for agents that binds the Ob-Re
US6743906B1 (en) * 1998-10-02 2004-06-01 Board Of Regents, The University Of Texas PPP2R1B is a tumor suppressor
US8034100B2 (en) 1999-03-11 2011-10-11 Endologix, Inc. Graft deployment system
US20030215423A1 (en) * 1999-04-01 2003-11-20 Merck & Co., Inc. Gene therapy for obesity
AU767068B2 (en) * 1999-06-11 2003-10-30 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of leptin activity
FR2836475B1 (fr) * 2002-02-26 2007-02-23 Aventis Pharma Sa Procede de detection de ligands du recepteur de la leptine
TW202417497A (zh) 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
LT3538554T (lt) 2016-11-08 2025-10-10 Antigeną surišantys baltymai, antagonizuojantys leptino receptorius
SG11202005146VA (en) 2017-12-18 2020-06-29 Regeneron Pharma Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof
PT3773713T (pt) 2018-04-06 2025-07-29 Regeneron Pharma Anticorpo agonista do recetor de leptina para usar no aumento da massa óssea num sujeito que sofre de disfunção metabólica ou de hipoleptinemia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988002757A1 (en) * 1986-10-17 1988-04-21 Saramane Pty. Ltd.; Hybrid proteins or polypeptides
ES2093017T3 (es) * 1989-07-20 1996-12-16 Tadamitsu Kishimoto Anticuerpo contra el receptor de la interleuquina-6 humana.
JP3403403B2 (ja) * 1990-03-23 2003-05-06 財団法人大阪バイオサイエンス研究所 顆粒球コロニー刺激因子レセプターをコードするｄｎａ
US5262522A (en) * 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
EP0804576B1 (de) * 1994-09-05 2008-09-03 Amrad Operations Pty.,Ltd. Hemopoietin-rezeptor
US5972621A (en) * 1995-11-27 1999-10-26 Millennium Pharmaceuticals, Inc. Methods of identifying compounds that modulate body weight using the OB receptor

Also Published As

Publication number Publication date
JP2003174895A (ja) 2003-06-24
DE69534196D1 (de) 2005-06-16
JP3479892B2 (ja) 2003-12-15
ES2242960T3 (es) 2005-11-16
DK0730606T3 (da) 2005-06-06
US6524806B1 (en) 2003-02-25
AU689948B2 (en) 1998-04-09
US5869610A (en) 1999-02-09
CA2176463C (en) 2006-07-11
CA2176463A1 (en) 1996-03-21
PT730606E (pt) 2005-09-30
DE69534196T2 (de) 2006-02-16
WO1996008510A1 (en) 1996-03-21
US6005080A (en) 1999-12-21
EP0730606A4 (de) 1997-03-12
US5643748A (en) 1997-07-01
EP0730606A1 (de) 1996-09-11
EP0730606B1 (de) 2005-05-11
AU3419495A (en) 1996-03-29
JPH10511079A (ja) 1998-10-27

Similar Documents

Publication Publication Date Title
DE69534196D1 (de) Hu-B1.219, EIN NEUARTIGER HÄMATOPOIETINREZEPTOR
HK13989A (en) Polynucleotide probes
NZ331866A (en) Compounds for immunotherapy and immunodiagnosis of prostate cancer
PT874645E (pt) Complexos metalicos contendo grupos perfluoroalquilo e sua utilizacao no diagnostico por rmn
AU1342888A (en) Molecules comprising at least one peptidic sequence carrying one or a plurality of epitopes characterizing a protein produced by P.Falciparum in hepatocytes and compositions containing them
GR3019849T3 (en) Acute pancreatitis associated protein and means for the diagnosis of acute pancreatitis
EP0947583A3 (de) Expressionsaktivierende Nukleinsäurefragmente des Melanom-inhibierenden Proteins (MIA)
WO1999027098A3 (en) A-33 related antigens and their pharmacological uses
WO1996040040A3 (en) Thrombin receptor homolog
HUT77029A (hu) A GAP-protein SH3 doménjéhez kötődni képes peptidek, ezeket kódoló nukleotidszekvenciák és előállításuk és alkalmazásuk
AP2000001917A0 (en) Gene encoding labyrinthin, a marker for cancer.
MX9709338A (es) Receptor de transmembrana-siete de tipo c5a.
CA2099503A1 (en) Synthetic alpha-l-iduronidase and genetic sequences encoding same
DK0643719T3 (da) Nukleinsyresekvenser, som koder for eller er komplementære til nukleinsyresekvenser, som koder for interleukin 9-receptor
ATE144791T1 (de) Innerhalb des alpha-locus gelegenes t-zell- rezeptor-gen und dna-konstruktionen
ATE229074T1 (de) Rekombinante chladosporium herbarum allergene
DE69526087D1 (de) Or-1, ein wais-rezeptor der nuklearen rezeptoren familie
EP0955374A3 (de) Retrovirale Gentransfervektoren
MX9703970A (es) Quimiocinas expresadas, su produccion y usos.
MX9709337A (es) Receptor p2u purinergico humano novedoso.
MX9706158A (es) Quimiocinas novedosas expresadas en pancreas.
WO1998012220A3 (en) Novel tumor proteins
MX9709747A (es) Serpina novedosa derivada de hipotalamo humano.
MX9704276A (es) Una quimiocina novedosa expresada en adenoides inflamadas, su produccion y usos.
MX9707852A (es) Homologo de fosfolipasa c.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0730606

Country of ref document: EP

REN Ceased due to non-payment of the annual fee